Innovative Biotech Solutions

Transforming Medicine with Advanced Therapies​

At Beijing Biotech, we integrate cutting-edge science with clinical application to revolutionize the treatment of complex medical conditions.

About Us

Leading the Way in Biotech Innovation and Collaboration

Beijing Biotech pioneers advanced cellular immunotherapies and regenerative medicine, reinforcing its position at the forefront of global biotech innovation through collaborations across the medical and research sectors. 

NK Cell Therapy & CAR-NK Cell Therapy in China

For families exploring advanced Immunotherapy for Cancer, Cell-based treatments like NK Cell Therapy, CAR-NK, and CAR-T Therapy can sound similar – yet they differ in targets, safety monitoring, and availability.


This page explains the basics in clear language, outlines a typical treatment journey in China, and shows how to compare programs in major medical hubs such as Beijing, Shanghai, Tianjin, Suzhou, Guangzhou, and Chengdu. 

Beijing Biotech is proudly based in Beijing, China

We manufacture and support cellular therapy workflows across multiple modalities (program-dependent) and collaborate with hospitals in China and with leading hospitals globally. Clinical decisions, eligibility, and treatment delivery are always made by the treating hospital’s licensed physicians.

Learn how NK Cell Therapy and CAR-NK therapy​​

Delivered in China for cancer treatment, including options in: Beijing, Shanghai, Guangzhou, and Chengdu.

This guide explains eligibility criteria for international patients, NK cell infusion timelines and processes, GMP manufacturing standards, and how to interpret CAR-NK success rates and safety data.

Explore CAR-NK vs CAR-T comparisons, potential side effects, hospital options in Beijing, cost and price factors, and available clinical trials for leukemia and B-cell lymphoma—while understanding how Beijing Biotech coordinates care from consultation to treatment completion.

What matters most when you evaluate an NK program:​

Cell source:

patient-derived (autologous) vs donor-derived (allogeneic) 

Manufacturing method:

activation/expansion approach, release testing, documentation 

Treatment setting:

registered clinical trial vs hospital program.

Monitoring plan:

who manages fever, low blood pressure, infections, and lab change.

Why Choose Beijing Biotech?​

Scientist in protective gear using a microscope for research in a laboratory setting.

           1.Innovative Therapies

                  2.Global Collaboration

                 3.Patient-Centric Support

        4.Research Excellence

Hear From Our Patients

testimonial skip 01.jpg
James Carter

Beijing Biotech provided exceptional support and clinical options that transformed my treatment journey. Their expertise is unmatched.

whatsapp image 2026 03 10 at 2.38.18 pm
Sun Yi Chen

The personalized approach taken by Beijing Biotech made a significant difference in my recovery. I’m truly grateful for their dedicated care.

testimonial skip 03.jpg
Michael Brown

I found hope through their innovative therapies. Their team made sure I was well-informed and supported throughout my entire treatment process.

Scroll to Top